Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
“We are tackling something that has not been done before. It is scientifically challenging, but the opportunity to make a difference within a few short years is what drives us.”
Azmi Nabulsi, MD, MPH
President & CEO, Vaderis Therapeutics
“We are tackling something that has not been done before. It is scientifically challenging, but the opportunity to make a difference within a few short years is what drives us.”
Azmi Nabulsi, MD, MPH
President & CEO, Vaderis Therapeutics
HHT is a rare vascular disease that can touch many organs and often goes unrecognized for years. What may begin as small, confusing symptoms can reflect fragile blood vessels throughout the body, leaving individuals and families searching for clarity and for care that goes beyond temporary relief.
The absence of approved therapies means that treatment today focuses mainly on managing complications. For the HHT community, this creates a long-standing gap between what medicine can address and what patients truly need. At Vaderis, we are driven to close this gap.
Our purpose is to transform promising vascular biology into real progress for patients who have had no proven options, and to bring a new sense of confidence and possibility to families who have lived with uncertainty for far too long. People with HHT deserve treatment that addresses the disease at its source and supports a future defined by stability, clarity, and hope. This is the future we are working to create.